A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF

NCT01326962 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: tocilizumab [RoActemra/Actemra]

Sponsor

Hoffmann-La Roche